Insulin Lispro Premix — Competitive Intelligence Brief

Insulin Lispro Premix (Insulin Lispro Premix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin premix. Area: Diabetes.

marketed Insulin premix Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Lispro Premix (Insulin Lispro Premix) — Eli Lilly and Company. Insulin lispro premix is a fixed combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics physiologic insulin secretion by providing both mealtime and basal glucose control.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Lispro Premix TARGET	Insulin Lispro Premix	Eli Lilly and Company	marketed	Insulin premix	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin premix class)

1. Eli Lilly and Company · 1 drug in this class